Brief: Glanbia expects FY adjusted EPS at upper end of guidance range
29/04/2026 07:00
April 29 (Reuters) - Glanbia PLC GL9.I: GLANBIA - Q1 GROUP LIKE-FOR-LIKE (LFL) REVENUE GROWTH OF 7.2% WITH STRONG VOLUME GROWTH ACROSS ALL THREE SEGMENTS (PRICING -1.0%) GLANBIA - Q1 PERFORMANCE NUTRITION (PN) LFL REVENUE GROWTH OF 11.5% WITH OPTIMUM NUTRITION LFL REVENUE GROWTH OF 18.8% (PRICING +2.3%) GLANBIA - Q1 HEALTH & NUTRITION (H&N) LFL REVENUE GROWTH OF 11.6% WITH VOLUME GROWTH OF 12.5% DRIVEN BY STRONG DEMAND ACROSS PRIORITY END-USE MARKETS (PRICING -0.9%) GLANBIA - Q1 DAIRY NUTRITION (DN) LFL REVENUE GROWTH OF 2.0% WITH STRONG VOLUME AND PRICING GROWTH IN PROTEIN SOLUTIONS (OVERALL PRICING -4.4%) GLANBIA - PROGRESS ON GROUP-WIDE TRANSFORMATION PROGRAMME, TARGETING ANNUAL SAVINGS OF AT LEAST $60M BY 2027 GLANBIA - FY 2026 ADJUSTED EPS EXPECTED TO BE AT THE UPPER END OF MEDIUM-TERM GUIDANCE OF 7% TO 11% CONSTANT CURRENCY GLANBIA - PN AND H&N REVENUES ARE NOW EXPECTED TO BE AT THE UPPER END OF THEIR MEDIUM-TERM GUIDANCE RANGES AND DN EBITDA IS NOW EXPECTED TO BE IN THE RANGE OF $160 MILLION TO $170 MILLION Further company coverage: GL9.I (Reporting By Padraic Halpin) ((Padraic.Halpin@thomsonreuters.com;))